Biomunex Announces Strategic Artificial Intelligence Collaboratio

Biomunex Pharmaceuticals announced strategic collaborations with Gordion Bioscience and Tangramed Biotech to integrate AI into its R&D and accelerate next-generation immunotherapy development in oncology.
The collaboration with Gordion Bioscience aims to identify novel bispecific target combinations for cancer therapy using computational target discovery and patient-derived biological network analysis.
The partnership with Tangramed Biotech will leverage generative AI and multimodal target-combination discovery to identify therapeutic opportunities using Biomunex’s proprietary BiXAb® platforms.
These collaborations aim to optimize target selection, shorten discovery timelines, and increase translational success in developing novel immunotherapies.
Biomunex is also focused on implementing AI across other areas of the company to enhance operations beyond R&D, including finance, HR, and legal departments.

You may have missed